SOLACI-CACI 2021 | SAC-FAC Session

✔️ Watch again the complete SAC-FAC Session in the SOLACI-CACI 2021 Congress.

👨‍🏫 Program:

– SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy

  • 01:06 – Optimal Medical Treatment in Patients with Cardiac Failure and Mitral Regurgitation – Florencia Renedo
  • 12:12 – Ultrasonographic Screening of Patients for Endovascular Therapy – Walter García
  • 25:43 – Mitral Valve Percutaneous Repair. Evidence. An Interventional Cardiologist’s Perspective – Jaime Fonseca

👉🏻 Chairpersons: Session I: Eduardo Perna
👉🏻 Panelists: Agüero, Marcelo – Cursack, Guillermo – Fernández Murga, Arturo – Garófalo, Pablo – Larribau, Miguel – Vigo, Santiago José

SESSION II: Medical Treatment and Revascularization in Patients with Chronic Coronary Syndrome

  • 53:09 – Optimal Medical Treatment – Juan Muntaner
  • 01:04:44 – Non-Invasive Diagnostic Methods – Roxana Campisi
  • 01:16:10 – Endovascular Revascularization – Daniel Berrocal

👉🏻 Chairpersons: Session II: Alejandro Hershson & Alejandro Machaín
👉🏻 Panelists: Comtesse, Daniel – Higa, Claudio – Moreyra, Eduardo – Navarro Estrada, José Luis – Pérez Baliño, Pablo – Tajer, Carlos – Swieszkowski, Sandra


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation, evidence level B, according to the current...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...